Your browser doesn't support javascript.
loading
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings.
Velthorst, Eva; Mollon, Josephine; Murray, Robin M; de Haan, Lieuwe; Germeys, Inez Myin; Glahn, David C; Arango, Celso; van der Ven, Els; Di Forti, Marta; Bernardo, Miguel; Guloksuz, Sinan; Delespaul, Philippe; Mezquida, Gisela; Amoretti, Silvia; Bobes, Julio; Saiz, Pilar A; García-Portilla, María Paz; Santos, José Luis; Jiménez-López, Estela; Sanjuan, Julio; Aguilar, Eduardo J; Arrojo, Manuel; Carracedo, Angel; López, Gonzalo; González-Peñas, Javier; Parellada, Mara; Atbasoglu, Cem; Saka, Meram Can; Üçok, Alp; Alptekin, Köksal; Akdede, Berna; Binbay, Tolga; Altinyazar, Vesile; Ulas, Halis; Yalinçetin, Berna; Gümüs-Akay, Güvem; Beyaz, Burçin Cihan; Soygür, Haldun; Cankurtaran, Eylem Sahin; Kaymak, Semra Ulusoy; Maric, Nadja P; Mihaljevic, Marina M; Petrovic, Sanja Andric; Mirjanic, Tijana; Del-Ben, Cristina Marta; Ferraro, Laura; Gayer-Anderson, Charlotte; Jones, Peter B; Jongsma, Hannah E; Kirkbride, James B.
Afiliação
  • Velthorst E; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. eva.velthorst@mssm.edu.
  • Mollon J; Seaver Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA. eva.velthorst@mssm.edu.
  • Murray RM; Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands. eva.velthorst@mssm.edu.
  • de Haan L; Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Germeys IM; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.
  • Glahn DC; Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands.
  • Arango C; Arkin Institute for Mental Health, Amsterdam, The Netherlands.
  • van der Ven E; Department of Neurosciences, Psychiatry Research Group, Center for Contextual Psychiatry, KU Leuven, Leuven, Belgium.
  • Di Forti M; Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bernardo M; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish Mental Health Research Network (CIBERSAM), Ma
  • Guloksuz S; Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Delespaul P; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Mezquida G; Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.
  • Amoretti S; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.
  • Bobes J; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.
  • Saiz PA; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • García-Portilla MP; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • Santos JL; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Jiménez-López E; Mondriaan Mental Health Care, Heerlen/Maastricht, The Netherlands.
  • Sanjuan J; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.
  • Aguilar EJ; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.
  • Arrojo M; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • Carracedo A; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • López G; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • González-Peñas J; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • Parellada M; Neurobiological Research Group, Institute of Technology, Universidad de Castilla-La Mancha, Cuenca, Spain.
  • Atbasoglu C; Department of Psychiatry, Hospital "Virgen de la Luz", Cuenca, Spain.
  • Saka MC; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • Üçok A; Universidad de Castilla-La Mancha, Health and Social Research Center, Cuenca, Spain.
  • Alptekin K; Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain.
  • Akdede B; Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain.
  • Binbay T; Department of Psychiatry, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Altinyazar V; Grupo de Medicina Xenómica, Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Galician Health Service (SERGAS), Santiago de Compostela, Spain.
  • Ulas H; Centro de Investigación en Red de Enfermedades Raras (CIBERER) y Centro Nacional de Genotipado (CEGEN-PRB3), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
  • Yalinçetin B; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • Gümüs-Akay G; Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
  • Beyaz BC; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish Mental Health Research Network (CIBERSAM), Ma
  • Soygür H; Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey.
  • Cankurtaran ES; Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey.
  • Kaymak SU; Department of Psychiatry, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Maric NP; Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
  • Mihaljevic MM; Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Petrovic SA; Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
  • Mirjanic T; Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
  • Del-Ben CM; Department of Psychiatry, Adnan Menderes University, School of Medicine, Aydin, Turkey.
  • Ferraro L; Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
  • Gayer-Anderson C; Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Jones PB; Department of Physiology, School of Medicine, Ankara University, Ankara, Turkey.
  • Jongsma HE; Brain Research Center, Ankara University, Ankara, Turkey.
  • Kirkbride JB; Department of Psychology, Middle East Technical University, Ankara, Turkey.
Mol Psychiatry ; 26(8): 4529-4543, 2021 08.
Article em En | MEDLINE | ID: mdl-33414498
ABSTRACT
Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = -0.45 to -0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = -0.14 to -0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = -0.88 to -0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = -0.13 to -0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = -0.21 to -0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Irmãos Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Irmãos Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos